Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their potential to “cut out” or influence physicians, the truth is that ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder PE: Can you elaborate on the key design elements of the AD04-13 study ...

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic graft-versus-host disease. The FDA has approved Incyte’s and Syndax’s Niktimvo ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas. With the start of the annual JP Morgan ...

Cigna Healthcare, the health benefits division of The Cigna Group, announced a new offering in collaboration with Progyny, Inc that will allow employers to offer fertility coverage that is more ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco. Over the past two years, the life sciences industry has seemingly fully embraced ...

The technology is part of a larger platform that provides a variety of AI-powered services. As people in the industry become more comfortable with the technology, AI is being used to find potential ...

Johnson & Johnson (J&J) announced that it has acquired Intra-Cellular Therapies, a biopharmaceutical company. According to the company, the acquisition includes Caplyta (lumateperone), a once-daily ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% complete response in patients with Bacillus Calmette-Guérin-unresponsive ...

The digital transformation of the pharmaceutical industry continues to provide innovative ways to improve the clinical research process. With the growing importance of strategies like real-time data ...

Teva Pharmaceuticals announced two strategic collaborations to expand its biosimilar portfolio and enhance access to high-cost biologics across key markets. The first deal, which is with Formycon AG ...